The story of Viagra presents a challenging picture for shareholders. While the initial launch generated significant gains, the end of its patent opened the avenue to off-brand alternatives, dramatically diminishing https://whitebookmarks.com/story21718627/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity